National Resource Center for Late Effects, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, and University of Oslo.
National Resource Center for Late Effects, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, and University of Oslo.
Ann Oncol. 2011 May;22(5):1062-1070. doi: 10.1093/annonc/mdq553. Epub 2010 Nov 3.
Whether systemic chemotherapy has a negative effect on cognitive function in patients, concern oncologists. In testicular cancer patients (TCPs) treated with cisplatin-based chemotherapy, only few cross-sectional studies have addressed this concern. We prospectively studied neuropsychological functioning in TCPs.
In a consecutive sampling, 122 TCPs were examined at baseline (after orchidectomy, before any additional treatment) and then at follow-up at a median of 12 months after end of treatment. The examinations included a neuropsychological test battery, interview on background variables and questionnaires on mental distress, fatigue and neurotoxic symptoms. Changes in neuropsychological functioning from baseline to follow-up were compared between three treatments groups: no chemotherapy (N = 31), one cycle of chemotherapy (N = 38) and two or more cycles of chemotherapy (N = 53). Variables associated with a decline in neuropsychological test performance from baseline to follow-up were explored.
No statistically significant differences in proportions of TCPs with a decline in neuropsychological test performance were observed between the three treatment groups. Decline in neuropsychological test performance was not associated with demographic variables, distress, fatigue or with chemotherapy.
No negative effect of systemic chemotherapy on neuropsychological test performance in TCPs at 1-year follow-up was found in this study.
全身化疗是否会对接受顺铂为基础化疗的睾丸癌患者的认知功能产生负面影响,这是肿瘤学家关注的问题。仅有少数横断面研究探讨了这一问题。我们前瞻性地研究了睾丸癌患者的神经心理学功能。
采用连续抽样的方法,在基线时(睾丸切除术后,任何其他治疗前)对 122 例睾丸癌患者进行检查,然后在治疗结束后中位数 12 个月时进行随访。检查包括神经心理学测试、背景变量访谈以及精神困扰、疲劳和神经毒性症状问卷。比较了三组治疗(无化疗组,N = 31;化疗 1 周期组,N = 38;化疗 2 周期或更多周期组,N = 53)之间从基线到随访时神经心理学功能的变化。探讨了与从基线到随访时神经心理学测试表现下降相关的变量。
三组治疗组之间,神经心理学测试表现下降的睾丸癌患者比例无统计学差异。神经心理学测试表现的下降与人口统计学变量、精神困扰、疲劳或化疗无关。
本研究未发现全身化疗对睾丸癌患者 1 年随访时神经心理学测试表现有负面影响。